Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Does sumatriptan cross the blood-brain barrier in animals and man?

Research output: Contribution to journalReviewResearchpeer-review

  1. PACAP38 and PAC receptor blockade: a new target for headache?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cilostazol induced migraine does not respond to sumatriptan in a double blind trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Further Questioning of the Significance of the Gepants: A Response

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Misused and Misleading: "100% Response Rate" to Galcanezumab in Patients With Episodic Migraine

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. Neurologisk undersøgelse i almen praksis: en oversigt baseret på hjemmsiden neurous.dk

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Sumatriptan, a relatively hydrophilic triptan, based on several animal studies has been regarded to be unable to cross the blood-brain barrier (BBB). In more recent animal studies there are strong indications that sumatriptan to some extent can cross the BBB. The CNS adverse events of sumatriptan in migraine patients and normal volunteers also indicate a more general effect of sumatriptan on CNS indicating that the drug can cross the BBB in man. It has been discussed whether a defect in the BBB during migraine attacks could be responsible for a possible central effect of sumatriptan in migraine. This review suggests that there is no need for a breakdown in the BBB to occur in order to explain a possible central CNS effect of sumatriptan.
Original languageEnglish
JournalJournal of Headache and Pain
Volume11
Issue number1
Pages (from-to)5-12
Number of pages7
ISSN1129-2369
DOIs
Publication statusPublished - 2009

Bibliographical note

Keywords: Animals; Blood-Brain Barrier; Central Nervous System; Dose-Response Relationship, Drug; Humans; Migraine Disorders; Serotonin Agonists; Sumatriptan

ID: 172941